domingo, 15 de diciembre de 2013

The ASCO Post

The ASCO Post

Time to Think Beyond KRAS in Metastatic Colorectal Cancer

By Caroline Helwick
December 1, 2013, Volume 4, Issue 19
Eric Van Cutsem, MD, PhD
The bottom line message from PRIME and FIRE-3, is that we should expand the testing of KRAS.
—Eric Van Cutsem, MD, PhD
Eric Van Cutsem, MD, PhD, Professor of Internal Medicine at the University of Leuven in Belgium, told attendees at the 2013 European Cancer Congress that in the management of metastatic colorectal cancer, it is time to expand KRAS testing to include more rare mutations.
Until recently, KRAS status was the only validated predictive biomarker in this disease, with KRAS-mutated tumors demonstrating resistance to inhibitors of the epidermal growth factor receptor (EGFR). But while KRAS wild-type patients are likely to respond to anti-EGFR agents, response is not universal, leading to the quest to find reasons for this lack of response.
“One of the next challenges has been to fine-tune, in this KRAS wild-type population, which patients will be responders and which will not,” Dr. Van Cutsem said.

No hay comentarios:

Publicar un comentario